Latest news

Half-Year Report

22 March 2023

Update on SDC-1801

15 March 2023

Notice of Half-Year Results

15 March 2023

Update on SRA737

06 March 2023

Find out more


TYK2/JAK1 inhibitor SDC-1801, targeting autoimmune diseases, is being prepared for first clinical studies

Find out more large-arrow.png


Sareum's innovative pipeline is focused on the TYK/JAK cell signalling family.

Find out more large-arrow.png

External Presentationssmall-arrow.png

IMC AGM, Dec 2022
IMC SDC-1801 CTA submission, Aug 2022
BioTrinity, April 2022

IMC Half Year Results, Feb 2022